We are building a pipeline focused on cardiometabolic diseases, including diabetes, obesity, and fatty liver, while continuing to develop innovative EndoEase™ platform capabilities.
Program |
Indication |
Target |
Class |
Delivery route |
Discovery |
Pre-clinical trial |
Clinical trial |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Diabetes
Obesity Fatty liver |
GLP-1 RAs |
Peptide |
Sublingual |
|
|
|
||||||||
|
SDM102 |
Endocrine disorders |
Undisclosed |
Hormone |
Sublingual |
|
|
|
|
||||||
|
SDM201 |
Infectious diseases
|
Undisclosed |
Vaccine |
Nasal spray |
|
|
|
|||||||
|
SDM301 |
Skin disorders |
Undisclosed |
Antibody |
Transdermal penetration |
|
|
|
